Japanese Korean Simplified Chinese Traditional Chinese 

Current Event 

Day 1
Day 2
Day 3  
PDF Download 
Press Pass 
Request Brochure 


Almac Diagnostics



Biomarkers in Medicine


The Scientist

Journal of Biological Markers

Bio-IT World





Drug Discovery News



Personalized Medicine




SelectScience logo

Translational Cancer Medicine


Top 10 Opportunities in Translational Cancer Medicine:

1. Combination Therapies
2. New Targets
3. Molecular Diagnostics
4. Companion Diagnostics
5. Better in vitro Models
6. Better in vivo Models
7. Biomarkers to Predict Drug Response
8. Cancer Biologics
9. Phase 0 Clinical Trials
10. Translational Imaging


Register for this event and receive
complimentary access to:

Biomarker Assay Development


Additional Coverage:

  • Case Studies in Oncology Drug Development
  • Cancer Biomarkers
  • Translation from In-House Development to Clinical Laboratory
  • Circulating Tumor Cell Assays


  • Novel Cancer Biomarkers
  • Fit-for-Purpose Biomarker Assay Development and Validation

Distinguished Faculty:

J. Carl Barrett, Ph.D., Global Head, Oncology Biomarker and Imaging, Novartis Institutes for BioMedical Research, Inc.

Richard Bender, M.D., FACP, Chief Medical Officer, Agendia, Inc.

Josip Blonder, M.D., Senior Research Scientist, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick Inc., NCI-Frederick

Walter Carney, Ph.D., Head, Oncogene Science, Siemens Healthcare Diagnostics, Inc.

Daniel Chelsky, Ph.D., Chief Science Officer, Caprion Proteomics

James Christensen, Ph.D., Director, Translational Pharmacology, Pfizer Global Research and Development

Martin Fleisher, Ph.D., Chair, Dept. of Clinical Laboratories, Memorial Sloan-Kettering Cancer Center

Herbert A. Fritsche, Ph.D., Professor and Chief, Clinical Chemistry, The University of Texas M. D. Anderson Cancer Center

John A. Gilly, Ph.D., Deputy Director, Biopharmaceutical Development Program, SAIC-Frederick/NCI-Frederick

Garret Hampton, Senior Director, Biochemistry & Biomarker Development, Celgene Research San Diego

Joerg Heyer, Ph.D., Principal Scientist, Group Leader, Genetic Models, AVEO Pharmaceuticals, Inc.

J. Milburn Jessup, M.D., Chief, Diagnostics Evaluation Branch, Cancer Diagnosis Program, DCTD/National Cancer Institute

Francis Kalush, Ph.D., Network Leader, Diagnostics, Office of the Center Director, Center for Devices and Radiological Health, Food and Drug Administration

Mark R. Lackner, Ph.D., Scientist, Developmental Oncology Diagnostics, Genentech, Inc.

Theresa LaVallee, Ph.D., Director, Translational Sciences Oncology, MedImmune

Syed Mahmood, M.D., Associate Medical Director, Clinical Imaging Physician, Oncology Clinical Imaging, Novartis Pharmaceuticals Corporation

Anne-Marie Martin, Ph.D., Director, Oncology, MDC, GlaxoSmithKline

Glenn Merlino, Ph.D., Chief, Laboratory of Cancer Biology and Genetics; Chief, Cancer Modeling Section, National Cancer Institute

Søren Møller, Ph.D., Vice President, Research and Development, Exiqon A/S

Bryce P. Nelson, Ph.D., Vice President, Research and Development, Gentel Biosciences

Scott D. Patterson, Executive Director of Medical Sciences, Amgen, Inc.

Shannon Payne, Ph.D., Senior Scientist, Epigenomics, Inc.

Gregory J. Riggins, M.D., Ph.D., Irving J. Sherman M.D. Professor of Neurosurgery Research, Professor of Neurosurgery & Oncology, Department of Neurosurgery, Johns Hopkins University

Frank Richardson, D.V.M., Ph.D., Senior Director, Preclinical Safety Assessment and Molecular Markers, OSI Pharmaceuticals, Inc.

Anderson Ryan, Ph.D., Principle Translational Scientist, Cancer BioScience, AstraZeneca

Jeffrey Shuster, Ph.D., Director, Diagnostics Development, Metabolon, Inc.

Jon M. Wigginton, M.D., Group Medical Director, Discovery Medicine - Oncology, Bristol-Myers Squibb Co.

Lin Wu, Ph.D., Director, Genomics & Oncology, Roche Molecular Systems, Inc.

By Series:
By Region: